

ACIP Dengue Vaccine Workgroup


Wilbur Chen, MD, MSc

ACIP Member and Workgroup Chair

Advisory Committee on Immunization Practices

ACIP Meeting October 20, 2022

Climate change will increase dengue incidence





FDA Licensure
(2019)
&
ACIP
Recommendation
(2021)



Three doses of Dengvaxia (0, 6, 12 months) are indicated for the prevention of dengue in individuals 9-16 years of age with laboratory confirmation of previous dengue virus infection and living in endemic areas.

New dengue vaccine under review

- Takeda TAK-003 dengue vaccine
- Completed phase 3 trials
- Proposal to present efficacy and safety data to ACIP in February 2023

Dengue Vaccine Workgroup Agenda

- Restarted August 30th
- Reviewed schedule and PICO questions
- Dengue vaccine safety and efficacy data

Presentations today

Dengue Epidemiology

Dr. Laura Adams, CDC, NCEZID, DVBD

Update on Dengvaxia Efficacy, Safety and Implementation

Dr. Gabriela Paz-Bailey, CDC, NCEZID, DVBD

ACIP Dengue Vaccines Workgroup

ACIP Members

Wilbur Chen (Chair)

Kathy Poehling

Beth Bell

Veronica McNally

CDC Co-Lead

Gabriela Paz-Bailey

Laura Adams

Ex Officio Members

Kaitlyn Morabito (NIH)

Ralph LeBlanc (FDA)

Ihid Carneiro (FDA)

Kirk Prutzman (FDA)

Srihari Seshadri (DOD)

Liaison Representatives

Elizabeth Barnett (AAP)

Rob Schechter (AIM)

Consultants

Edwin Asturias

Robert Atmar

Alan Barrett

Iris Cardona

Anna Durbin

Tony Marfin

Hal Margolis

Kristen Pierce

Anita Shet

CDC Contributors

Josh Wong

Mimi Eckert

Rachel Eidex

Alfonso Hernandez

Susan Hills

Terri Hyde

Mike McNeil

Jorge Munoz

Erin Staples

Cindy Weinbaum

Rita Helfand